^
    CANCER:

    Gastrointestinal Cancer

    No biomarker
    Esophageal Squamous Cell Carcinoma
    sintilimab
    Sensitive: A1 - Approval
    Innovent Biologics Press Release - 5 days - (New A1)
    No biomarker
    HCC
    durvalumab + CP-675206
    Sensitive: B - Late Trials
    NEJM Evidence - 2 weeks - (New B)
    MSI-H/dMMR
    Small Intestinal Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    Ann Oncol - 2 weeks - (New C3)
    MSI-H/dMMR
    Gastric Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    Ann Oncol - 2 weeks - (New C3)
    NRAS mutation
    CRC
    bevacizumab
    Sensitive: C2 – Inclusion Criteria
    ESMO Open - 2 weeks - (New C3)
    KRAS mutation
    CRC
    bevacizumab
    Sensitive: C2 – Inclusion Criteria
    ESMO Open - 2 weeks - (New C3)
    LRP1B mutation + TP53 wild-type
    HCC
    lenvatinib
    Resistant: C3 – Early Trials
    Hepatol Int - 2 weeks - (New C3)
    FAT1 mutation + TP53 wild-type
    HCC
    lenvatinib
    Resistant: C3 – Early Trials
    Hepatol Int - 2 weeks - (New C3)
    PD-L1 expression
    Gallbladder Cancer
    bevacizumab
    Sensitive: C4 – Case Studies
    Dovepress - 2 weeks - (New C4)
    RNF43 G659fs
    CRC
    PI3K inhibitor
    Sensitive: D – Preclinical
    Nat Commun - 2 weeks - (New D)
    RNF43 G659fs
    CRC
    mTOR inhibitor
    Sensitive: D – Preclinical
    Nat Commun - 2 weeks - (New D)
    RNF43 659
    CRC
    mTOR inhibitor
    Sensitive: D – Preclinical
    Nat Commun - 2 weeks - (New D)
    RNF43 659
    CRC
    PI3K inhibitor
    Sensitive: D – Preclinical
    Nat Commun - 2 weeks - (New D)
    HER-2 amplification
    CRC
    trastuzumab + pertuzumab
    Sensitive: A2 - Guideline
    JCO Clin Cancer Inform - 3 weeks - (New C3)
    BRAF V600E
    CRC
    bevacizumab
    Sensitive: B - Late Trials
    Br J Cancer - 3 weeks - (New C3)
    HER-2 positive
    Biliary Tract Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: C1 - Off-label
    J Clin Oncol - 3 weeks - (New C3)
    FGFR4 expression
    HCC
    PDR001 + FGF401
    Sensitive: C3 – Early Trials
    J Exp Clin Cancer Res - 3 weeks - (New C3)
    KLB expression
    HCC
    PDR001 + FGF401
    Sensitive: C3 – Early Trials
    J Exp Clin Cancer Res - 3 weeks - (New C3)
    HER-2 G776S
    CRC
    afatinib
    Sensitive: D – Preclinical
    Sci Rep - 3 weeks - (New D)
    YAP1 overexpression
    HCC
    sorafenib + CA3
    Sensitive: D – Preclinical
    Cancers (Basel) - 3 weeks - (New D)
    TAFAZZIN overexpression
    HCC
    sorafenib + CA3
    Sensitive: D – Preclinical
    Cancers (Basel) - 3 weeks - (New D)
    APC mutation
    CRC
    HMG-CoA reductase inhibitor
    Sensitive: D – Preclinical
    Front Oncol - 3 weeks - (New D)
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    cisplatin + 5-fluorouracil + docetaxel
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    nivolumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive: A1 - Approval
    BRCA2 mutation
    Pancreatic Cancer
    olaparib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    bevacizumab + atezolizumab
    Sensitive: A1 - Approval
    BRCA1 mutation
    Pancreatic Cancer
    olaparib
    Sensitive: A1 - Approval
    FGFR2 rearrangement
    Cholangiocarcinoma
    infigratinib
    Sensitive: A1 - Approval
    FGFR2 fusion
    Cholangiocarcinoma
    infigratinib
    Sensitive: A1 - Approval
    IDH1 mutation
    Cholangiocarcinoma
    ivosidenib
    Sensitive: A1 - Approval
    MSI-H/dMMR
    CRC
    pembrolizumab
    Sensitive: A1 - Approval
    MSI-H/dMMR
    CRC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    TPF
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    TPF
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive: A1 - Approval
    BRAF V600E
    CRC
    cetuximab + encorafenib + binimetinib
    Sensitive: A1 - Approval
    BRAF V600E
    CRC
    cetuximab + encorafenib
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    FOLFIRI
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    5-fluorouracil + irinotecan
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Squamous Cell Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    CRC
    bevacizumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    nivolumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 negative + PD-L1 expression
    Gastric Cancer
    nivolumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    trastuzumab
    Sensitive: A1 - Approval
    No biomarker
    Esophageal Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Trazimera (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ontruzant (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Ogivri (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Kanjinti (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Herzuma (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    Mvasi (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    Zirabev (bevacizumab biosimilar)
    Resistant: A1 - Approval
    No biomarker
    CRC
    trifluridine / tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    trifluridine / tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    trifluridine / tipiracil
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Adenocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    cabozantinib tablet
    Sensitive: A1 - Approval
    No biomarker
    CRC
    ziv-aflibercept IV
    Sensitive: A1 - Approval
    No biomarker
    Gastric Cancer
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    CRC
    capecitabine
    Sensitive: A1 - Approval
    No biomarker
    Pancreatic Cancer
    erlotinib
    Sensitive: A1 - Approval
    EGFR expression
    CRC
    cetuximab
    Sensitive: A1 - Approval
    KRAS Q61
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    CRC
    ramucirumab
    Sensitive: A1 - Approval
    KRAS A146
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    Gastroesophageal Junction Adenocarcinoma
    ramucirumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    No biomarker
    Rectal Cancer
    irinotecan
    Sensitive: A1 - Approval
    No biomarker
    Colon Cancer
    irinotecan
    Sensitive: A1 - Approval
    No biomarker
    HCC
    sintilimab + Byvasda (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive: A1 - Approval
    PD-L1 expression
    Esophageal Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    AFP elevation
    HCC
    ramucirumab
    Sensitive: A1 - Approval
    No biomarker
    HCC
    regorafenib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    lenvatinib
    Sensitive: A1 - Approval
    No biomarker
    HCC
    sorafenib
    Sensitive: A1 - Approval
    KRAS G13
    CRC
    cetuximab
    Resistant: A1 - Approval
    KRAS G12
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    CRC
    Aybintio (bevacizumab biosimilar)
    Sensitive: A1 - Approval
    MSI-H/dMMR
    CRC
    nivolumab
    Sensitive: A1 - Approval
    HER-2 overexpression
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    MSI-H/dMMR
    Biliary Tract Cancer
    pembrolizumab
    Sensitive: A1 - Approval
    FGFR2 rearrangement
    Cholangiocarcinoma
    pemigatinib
    Sensitive: A1 - Approval
    FGFR2 fusion
    Cholangiocarcinoma
    pemigatinib
    Sensitive: A1 - Approval
    No biomarker
    CRC
    regorafenib
    Sensitive: A1 - Approval
    KRAS K117
    CRC
    cetuximab
    Resistant: A1 - Approval
    KRAS A59
    CRC
    cetuximab
    Resistant: A1 - Approval
    No biomarker
    HCC
    nivolumab + ipilimumab
    Sensitive: A1 - Approval
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive: A1 - Approval
    KRAS G12S
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS Q61
    CRC
    cetuximab
    Resistant: A1 - Approval
    NRAS Q61
    CRC
    panitumumab
    Resistant: A1 - Approval
    NRAS G13
    CRC
    panitumumab
    Resistant: A1 - Approval